Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Skyhawk-Therapeutics

More Like This

PR Newswire associated0

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

PR Newswire associated0

Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease

PR Newswire associated0

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

Hyku Biosciences Launches With $56M to Advance its Covalent Medicines Platform to Expand the Boundaries of Drug Discovery

MiLaboratories co-founders: Dmitry Chudakov, Stan Poslavsky, Dmitry Bolotin, Alexey Nechaev (Photo: Business Wire)

MiLaboratories Secures Series A, Raising Total Funding to $10 Million to Revolutionize the World of Genomic Research

EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease

From left to right: Altasciences' Dr. Lynne Le Sauteur, Dr. Susan Ohorodnik, Ian Vanterpool, and Michael Qualls at the bioanalytical laboratory opening in Columbia, Missouri (Photo: Business Wire)

Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri